MedElevator Войти в исследования
← Поиск публикаций

DOI 10.7759/cureus.53992

Медицинская библиотека · Cureus · 2024

Prevalence and Comorbidities Among Individuals With Rheumatoid Arthritis in the Saudi Arabian Context.

Alghamdi Mushabab, Somaily Mansour Y, Alemam Shahenda, Majadah Saeed, Hassan Abduaelah Ali H, Meshary Abdullah A, Alasmri Saad Ahmad A, Ali Munif S, Alsubaie Abdullah A, Miskeen Elhadi

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Rheumatoid arthritis (RA) in Saudi Arabia (SA) is a significant health concern with a notable impact on individuals and the healthcare system. This study aimed to investigate the prevalence and profile of comorbidities in patients with RA.

METHODOLOGY: This is a retrospective descriptive study involving 150 RA patients from August 2022 to August 2023, which was conducted at Khamis Mushait General Hospital, a major healthcare institution in SA. We examined the medical records to gather pertinent information. Stata Statistical Software: Release 18 (2023; StataCorp LLC, College Station, Texas, United States) was used for data analysis. The examination focused on sociodemographic factors, disease duration, prescribed medications (including methotrexate and biologic therapy), and the presence of comorbidities. Approval for the study was obtained from the Institutional Review Board of the Aseer Ministry of Health (approval number: H-06-B-091).

RESULTS

The study found a high prevalence of comorbidities in patients with RA. Around 96.7% of the patients had at least one documented comorbidity, highlighting this population's burden of additional health conditions. The most common comorbidity observed was anemia, affecting 48.7% of the patients. Other frequently observed comorbidities include hypertension, hyperlipidemia, diabetes mellitus, osteoporosis, interstitial lung disease, chronic renal disease, stroke, and coronary artery disease. The factors influencing comorbidities included an odds ratio of 1.086 (p=0.025), while being male was associated with lower odds (odds ratio=0.529, p=0.017). Additionally, disease duration (odds ratio=1.164, p=0.007), methotrexate use (odds ratio=2.553, p=0.001), and receiving biologic therapy (odds ratio=3.488, p<0.001) were significant contributors to comorbidities.

CONCLUSION

These findings highlight the need for comprehensive approaches to address RA and its associated comorbidities. Research and awareness initiatives are essential to understand better the specific nuances of RA in SA, leading to improved diagnostic and treatment strategies for the needs of the local population.

Для цитирования: Alghamdi Mushabab, Somaily Mansour Y, Alemam Shahenda, Majadah Saeed, Hassan Abduaelah Ali H, Meshary Abdullah A, Alasmri Saad Ahmad A, Ali Munif S, Alsubaie Abdullah A, Miskeen Elhadi. Prevalence and Comorbidities Among Individuals With Rheumatoid Arthritis in the Saudi Arabian Context.. Cureus. 2024. DOI: 10.7759/cureus.53992.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.